Status:
COMPLETED
Open-Label Study of Omega 3 Oil Supplementation for Aging-Related Cognitive Decline
Lead Sponsor:
Neurological Associates of West Los Angeles
Collaborating Sponsors:
Prodrome Sciences
Conditions:
Cognitive Decline
Eligibility:
MALE
35-65 years
Phase:
NA
Brief Summary
Aging-related cognitive decline may be affected by brain cholesterol and the health of cell membranes. Certain nutritional supplements have been proposed to support membrane health, and there is incre...
Detailed Description
There has been an increasing interest in plasmalogens as a potential therapeutic agent for age-related cognitive decline and neurodegenerative conditions, given the growing understanding of their invo...
Eligibility Criteria
Inclusion
- Cognitive decline due to aging-related changes
- Clinical Dementia Rating stage of mild dementia 0.5 through moderate dementia CDR stages 1 and 2
Exclusion
- Subjects unable to give informed consent
- Cognitive decline clearly related to an acute illness
- Subjects taking anticoagulants and anti-platelet agents
- Advanced terminal illness
- Any active cancer or chemotherapy
- Any other neoplastic illness or illness characterized by neovascularity
Key Trial Info
Start Date :
July 17 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 13 2021
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04484454
Start Date
July 17 2020
End Date
March 13 2021
Last Update
June 7 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Neurological Associates of West Los Angeles
Santa Monica, California, United States, 90403